Hope on the Horizon: Can Cell-Based Therapies Cure Huntington's Disease?
"Exploring the potential of stem cell treatments to revolutionize care for Huntington's Disease, offering a beacon of hope for patients and families affected by this devastating genetic disorder."
Huntington's disease (HD) is a devastating inherited disorder characterized by the progressive breakdown of neurons in the brain. This relentless deterioration of physical and mental abilities has no cure, leaving patients and their families with limited options. However, the landscape of HD treatment is evolving, with cell-based therapies emerging as a promising avenue of exploration.
Cell-based therapies offer a unique approach by targeting the underlying mechanisms of the disease. Unlike traditional treatments that only manage symptoms, these therapies aim to repair or replace damaged cells, potentially slowing or even halting disease progression. In HD, this means exploring ways to replace lost neurons or protect existing ones from further damage.
This article delves into the cutting-edge research on cell-based technologies for HD, examining various approaches, including human fetal tissue (hFT), neural stem cells (NSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs). We will also discuss the use of mesenchymal stem cells (MSCs), derived from non-neural tissues, and the progress made in preclinical and clinical studies.
From Disease Biology to Cell Therapy
Huntington’s disease is caused by an autosomal dominant mutation involving an abnormal CAG repeat expansion, which leads to production of the toxic misfolded mutant huntingtin protein. Reviews describe a research field that has expanded beyond palliative treatment into stem cells, gene therapy, and three-dimensional cell structures called organoids. Despite this progress, current treatments remain limited to symptom relief, while stem-cell-based clinical research is still in its early stages.
Cell-Based Therapies: A New Frontier in HD Treatment
The primary goal of cell-based technologies is to restore the mechanisms underlying disease initiation and progression. This is achieved both through the replacement of dead or defective cells and through the "trophic effect," where certain cell types stimulate recovery after being transplanted into the damaged site. Several cell types are being explored for these therapies:
- Neural Stem Cells (NSCs): NSCs are self-renewing cells able to generate neurons, glial cells, and astrocytes. NSCs can be derived from embryonic, fetal, or adult tissues. Studies have shown that transplantation of NSCs improves motor function, extends life span and even lessens mHTT intracellular aggregate formation.
- Embryonic Stem Cells (ESCs): ESCs are pluripotent cells isolated from the inner cell mass of early embryos. To analyze the therapeutic potential of human ESCs in HD animal models, they have been reversed to NPCs that have been transplanted directly into the striatum of the animal models.
- Induced Pluripotent Stem Cells (iPSCs): Laboratory-grown iPSCs are a type of pluripotent cell that can be generated directly from adult cells. The iPSCs share all principal characteristics of ESCs, having the ability of long-term self-renewal, maintaining an unspecialized state; and giving rise to (under specific treatments) specialized cell types and teratomas when injected in vivo. After transplantation, a modest reduction in striatal neuronal atrophy, a hallmark of HD disease that appears before the onset of motor symptoms, can be observed.
- Mesenchymal Stem Cells (MSCs): MSCs can be found in virtually all postnatal tissues, including the embryonic annexes (umbilical cord and placenta), bone marrow and adipose tissue. These studies demonstrate that MSC transplantation leads to behavioral and memory improvements, reduced brain damage, improvement of striatal degeneration, and enhanced expression of several striatal growth factors, which are attributed to the neuroprotective effect of MSCs.
Research Moves Toward Clinical Testing
Recent reviews identify stem cells, gene therapy, and organoids as active areas of Huntington’s disease research. A phase II randomized, double-blind, placebo-controlled trial enrolled 35 patients to receive human dental pulp stem cells at 1 million cells/kg, 2 million cells/kg, or placebo across nine intravenous infusions over 11 months. Separately, the STAR study is described as a phase 3 multicenter randomized, double-blind, placebo-controlled trial planned to enroll 120 patients with Huntington’s disease.
Promising Models, Unresolved Barriers
Preclinical studies using murine or human neural stem cells have reported improved motor function, extended lifespan, and reduced intracellular mutant huntingtin aggregates in Huntington’s disease animal models. However, Huntington’s disease still has no cure, and the limitations of fetal-derived donor cells have driven efforts to develop neuronal and glial progenitors from human pluripotent stem cells. The field is therefore pursuing evidence-based guidance and best practices to determine whether this complex strategy can be used reliably in treatment.
Comparing Therapeutic Strategies
The therapeutic landscape now includes stem-cell technology, gene therapy, and neuroprotective strategies rather than symptom management alone. Evidence for stem-cell transplantation or its derivatives is strong in Huntington’s disease animal models, but preclinical and clinical trials remain at an early stage. No stem-cell source is approved for Huntington’s disease, and candidate cell sources may differ in whether their intended role is replacing lost striatal neurons, protecting surviving cells, or doing both.
The Future of Cell-Based Therapies in HD
Cell-based therapies represent a significant leap forward in the quest to treat and potentially cure Huntington's disease. While challenges remain, the progress made in recent years offers a renewed sense of hope for those affected by this devastating condition. As research continues and technology evolves, these therapies hold the promise of transforming HD from an incurable illness into a manageable or even curable condition.
A Field Approaching Its First Clinical Milestones
An update presented at the ISSCR 2026 Annual Meeting described the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington’s disease. Another 2026 report says that gene therapies such as AMT-130 are beginning to slow disease progression, although that report frames the development as an emerging shift rather than a definitive cure. Together, these developments point toward testing both cell-based and gene-based approaches to alter the course of the disease.
From Laboratory Promise to Patient Care
UCI Health reported that the first patient received neural stem cell therapy in REGEN4HD, described as the world’s first in-human embryonic stem cell-derived clinical trial for Huntington’s disease. The phase 1b/2a trial is evaluating the safety of hNSC-01 neural stem cells. UCI Health also describes Huntington’s disease as a fatal, progressive disorder that gradually destroys brain cells and remains without a therapy shown to slow it.